Abstract:Objective Durable hepatitis B virus (HBV)DNA suppression is important to antiviral effectiveness in chronic hepatitis B (CHB). In this study,we analyzed the long-term efficacy and resistance profile of entecavir (ETV) monotherapy in 20 Chinese patients with nucleoside nave CHB treated for at least 5 years. Methods Twenty HBeAg positive patients with HBV DNA level 107 copies/mL and alanine aminotransferase (ALT)level 2-fold upper limit of normal (ULN)received ETV 0.5 or 1 mg/day for accumulated 5 years. Serum HBV DNA level,HBeAg status and HBsAg level were assessed at baseline and at year 1 ,2 ,3 ,4 and 5 . Gene sequencing was also conducted in the patients whose serum HBV DNA level > 300 copies/mL at year 5 . Results The ratio of HBV DNA undetectable (<300 copies/mL)for these 20 patients were 60% ,40% ,50% ,85% and 85% at year 1,2,3,4 and 5 respectively. The ratios of HBeAg loss were 15% ,15% ,20% ,30% and 65% at year 1,2,3,4 and 5,respectively. Three of 20 patients (15% )achieved HBeAgseroconversion at year 4 and 5 . Variables were compared between the patients whose serum HBV DNA < 300 copies/mL and those of patients > 300 copies/mL at week 48. Virological response rate was 100% and 66.7% at week 240 in the former's and the latter's,respectively;HBeAg seroconversion rate was 27.3% and 0 at week 240 in the former's and latter's, respectively. Virological response rate was 100% at week 240 in the patients whose ALT level 2-fold ULN,and was only 75% in the patients whose ALT level < 2-fold ULN;Meanwhile,the rate of HBeAg seroconversion was 37.5% and 0 in the former's and latter's. The rate of HBeAg seroconversion was 1 1 .1% at week 240 in the patients whose HBV DNA level>108 copies/mL at baseline,and was only 50% in the patients whose HBV DNA level <108 copies/mL at baseline,the statistics had significant difference (P<0.05). The mean serum HBsAg levels of the patients were (4.04±0.40)log10 IU/mL,(3.64±0.44)log10 IU/mL,(3.73±0.41)log10 IU/mL,(3.53±0.55)log10 IU/mL,(3.55±0.55)log10 IU/mL and (3.55±0.63)log10 IU/mL at baseline and at year 1,2,3,4 and 5,respectively. HBsAg levels had a greater mean reduction at year 1 (P= 0.005),3 (P= 0.005),4 (P= 0.009)and 5 (P= 0.018)compared with baseline, respectively. The HBsAg titers at baseline were significantly different between the patients whose HBeAg loss (3.95 ± 0.54)log10 IU/mL and HBeAg non-loss (4.20±0.48)log10 IU/mL at week 240 (P= 0.005). Non adverse effect was observed in this study. Conclusion These analysis demonstrates that long-term treatment of ETV monotherapy is effective in maintaining viral suppression. No ETV resistance substitution are detected in these patients.

Phenotypic assay of hepatitis B virus isolates from one treatment-nave patient with entecavir resistance

Correlation Between Serum Entecavir Concentration And Virological Response In Patients With Chronic Type B Hepatitis

Dynamics of Lamivudine-Resistant Hepatitis B Virus Strains in Patients with Entecavir Rescue Therapy.

Selection and clearance of entecavir-resistant HBV strains in lamivudine-resistant hepatitis B patient treated with entecavir:A case report

Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance

Phenotypic Assay of a Hepatitis B Virus Strain Carrying an Rts246t Variant Using a New Strategy

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated with Long-Term Entecavir Treatment Determined with Ultradeep Pyrosequencing

Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.

Long term efficacy of entecavir therapy on viral suppression in nucleoside-nave chronic hepatitis B patients

Identification of a Novel Entecavir-Resistant Mutation Rtl180m+a186t+m204v of Hepatitis B Virus

Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient

Association Between Hepatic Steatosis And Entecavir Treatment Failure In Chinese Patients With Chronic Hepatitis B

Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.

A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study

Evolution of Entecavir-Resistant Hepatitis B Virus During Entecavir and Adefovir Dipivoxil Combination Therapy.

Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.

Complexity and Diversity of Hepatitis B Virus Quasispecies: Correlation with Long-Term Entecavir Antiviral Efficacy.

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

Evolutionary Patterns of Hepatitis B Virus Quasispecies under Different Selective Pressures: Correlation with Antiviral Efficacy

Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis